石明博士为和黄医药执行副总裁、研发负责人兼首席医学官。他负责带领公司的药物发现和临床开发战略和执行。

于2022年加入和黄医药前，石博士曾任创胜集团的全球研发负责人兼首席医学官，在中国和美国建立了一个强大的全球研发团队，并将七个项目推进临床开发及多项临床前候选药物提名。在此之前，石博士在诺华工作超过15 年，担任过多个高级领导人员职位，包括全球项目临床负责人，并在多个新型肿瘤/ 血液病产品的临床开发中发挥了关键领导作用，包括从临床概念验证到成功执行全球关键试验、产品注册和生命周期管理。

石博士拥有南加州大学分子药理学和毒理学博士学位，并于哈佛大学医学院进行博士后研究。他在北京协和医学院完成其医学学位。

Dr Michael Shi is the Executive Vice President, Head of R&D and Chief Medical Officer of HUTCHMED. He oversees the drug discovery and development of the company from strategy to execution.

Prior to joining HUTCHMED in 2022, Dr Shi was the Global Head of R&D and Chief Medical Officer at Transcenta Holding Limited where he helped build a strong global research and development organization across China and the U.S. and advanced seven programs into clinical development and multiple preclinical candidate nominations. Before that, Dr Shi worked at Novartis for over 15 years, where he held various senior leadership positions including global program clinical head in clinical development. He played key leadership roles in the clinical development of multiple novel oncology/hematology products from clinical proof-of-concept to successful execution of global pivotal trials, product registration and lifecycle management. 

Dr Shi holds a PhD in Molecular Pharmacology and Toxicology from the University of Southern California, and conducted postdoctoral research at the Harvard Medical School. He received his medical education from Peking Union Medical College.